Jardiance 25mg Tab

Manufacturer
Boehringer Ingelheim


 
Content

• Active Ingredient: Each tablet contains 25 mg of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults:
  • Monotherapy when metformin is inappropriate due to intolerance.
  • Add-on combination therapy with other glucose-lowering medications.
• Cardiovascular Disease: To reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
• Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure.
• Chronic Kidney Disease: To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.

• Dosage: The recommended starting dose is 10 mg once daily. If additional glycemic control is needed and the patient tolerates 10 mg, the dose may be increased to 25 mg once daily.
• Administration: Take the tablet in the morning, with or without food. Swallow the tablet whole with a glass of water.
• Missed Dose: If a dose is missed, take it as soon as possible unless it's almost time for the next dose. Do not take two doses at the same time to make up for a missed dose.
• Renal Function: Assess renal function before initiating treatment and periodically thereafter. Jardiance is not recommended for use in patients with an eGFR less than 30 mL/min/1.73 m².